Orphan drug developer. Oncology and immunological diseases


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Anviron: Fast Facts

Devastating Pancreatic Cancer

Our Novel Approach: Correct dysregulated mRNA folding

Pancreatic Cancer is one of many cancers that upregulate mRNA protein folding mechanisms to drive a multitude of proliferative and aberrant behaviors. Enzyme DPAGT1 is the first step in dysregulated protein folding. The challenge is inhibiting this enzyme only in cancer while avoiding healthy cells.

Leveraging our team’s expertise with mRNA glycobiology and protein synthesis, Anviron developed our leading candidate, ANV221, a well tolerated inhibitor of DPAGT1 resulting in a reduction or elimination of pancreatic tumors in vitro and mouse models.

Comparison Study:

ANV221 was superior to standard of care Gemcitabine in solid tumor studies and significantly superior to Gemcitabine and Paclitaxel in metastasis suppression.

Our team also found that DPAGT1 inhibition led to other morphology changes that made cancer cells more vulnerable to cytotoxic therapies.

Our next step with ANV221 is human trials to establish degree of efficacy over and in combination with standard of care drugs.

Fast-Tracked Development

Our leading therapy for pancreatic cancer was given Orphan Drug Designation by the FDA in October 2021, giving tax advantages along with market exclusivities.

Anviron has an established proof-of-concept and IP for multiple therapies. We have a very strong IP/patent portfolio

We are partnered with world class research institutions to advance and expand our pipeline of oncology and immunological candidates.

Meet The Team

Additional team members include: Julie Tran, MBA, Regulatory Affairs Advisor; Kimberly Brown, Sr. Proteomics Scientist, Novozymes; Jane Burns, MD, Clinical Advisor; Krista Frederickson, MBA, Business Advisor and Lawrence Fridhoff, Regulatory Advisor;

This presentation and any accompanying oral presentation contain “forward-looking” statements that are based on our management’s current expectations and projections about future events and trends that we believe may affect our business, financial condition, operating results and growth prospects. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information relating to future events or our future financial or operating performance; our expectations with respect to development plans for our product candidates; and the potential timing and success of future clinical trials. Factors that could cause our results and expectations to differ materially from those expressed in forward-looking statements include, without limitation, our need for additional funds to support our operations; our success being dependent on our product candidates; uncertainties inherent in the clinical drug development process, including lengthy, time consuming and inherently unpredictable regulatory reviews and delays in clinical trials; product candidates may cause serious adverse side effects or have properties that delay or prevent regulatory approval or limit their commercial profile; if approved, risks associated with market acceptance, including pricing and reimbursement; and risks related to intellectual property litigation. Our forward-looking statements relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.